This study illustrates the healthcare utilization patterns, direct costs, and sustained virologic response rates associated with interferon-based therapies for hepatitis C patients.
Yvonne C. Jonk, PhD
Advertisement
Articles by Yvonne C. Jonk, PhD
Advertisement
Latest Updated Articles
- Interferon-Based Therapies for Hepatitis C: Utilization, Costs, and Outcomes
Published: February 8th 2013 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
2
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
3
Breaking News: CVS Buys Rite Aid, Bartell Drugs
4
Current and Emerging BCMAxCD3 Bispecifics
5
